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Clenbuterol is a recently synthesised sympathomimetic agent with a specific affinity for the P2-adrenergic receptors in the bronchial musculature. Animal studies have shown that its bronchodilator action is more prolonged than that of orciprenaline and salbutamol (Engelhardt, 1976) . The purpose of this study was to compare in a double-blind cross-over manner the effects of clenbuterol, salbutamol, and placebo in patients with bronchial asthma.
Patients and methods
Nineteen patients with bronchial asthma were studied. All showed an improvement in peak expiratory flow rate (PEFR) exceeding 15% five minutes after inhaling 2 puffs (0 16 mg) of isoprenaline. The characteristics of the patients are shown in Table 1 . All bronchodilator drugs were stopped at least 10 hours before the trial, but patients taking corticosteroids and sodium cromoglycate continued to do so.
After giving informed consent patients were trained to record PEFR following the method of Lal et al. (1974) . On a practice day before the trial they were instructed on rising to make three technically acceptable readings of PEFR at 10- Patients recorded a subjective impression of their breathing during the test day. This was compared to that on the day before the trial and scored as 1, worse; 2, no change; 3, a little better; 4, much better; 5, very much better. Patients were told to contact the physician if any difficulties were experienced during the trial period.
After completing the practice day patients were studied over three consecutive days and were given sealed packets each containing three tablets, two white and one coloured. Each patient was given in random order the following drugs: placebo day, two white tablets (placebo) and one blue tablet (placebo); salbutamol day, two white tablets (placebo) and one pink tablet (4 mg salbutamol); clenbuterol day, two white tablets (2X20 ,ug clenbuterol) and one yellow tablet (placebo). It has been shown that salbutamol, 4 mg, gives a bronchodilatation effect equivalent to clenbuterol, 40 ,ug (Kamburoff et al., 1977) . The tablets were taken between 0800 and 0900 hours, immediately after obtaining basal values for PEFR. PEFR was then recorded at the same intervals as on the practice day and similar recordings were made of sideeffects and breathing scores. Patients were studied as outpatients and were interviewed after the practice day to ensure that they were able to cope with the methods of the trial. 717 G. Anderson and E. Wilkins Analysis of variance was carried out at each time-point on the patients' PEFR readings, and Duncan's multiple range test was used to investigate further any differences between treatments. Subjective assessments of breathing were analysed by a Friedman two-way analysis of variance (Siegel, 1956) .
Results
The results of mean PEFR in 19 patients are shown in Table 2 . During the placebo day there was a slow rise in PEFR until four hours after recording the basal values, when a plateau was reached. These increases were significant (P<0-05) at 10 minutes and from one to eight hours. With salbutamol there was a significant (P<0-05) increase above the baseline values from 20 minutes onwards, the increase being highly significant (P<0-01) from 30 minutes to eight hours. Clenbuterol showed a significant increase at every timepoint, the increase being highly significant (P<0 01) from 20 minutes to 10 hours.
With both salbutamol and clenbuterol there were significant (P<0-05) differences from placebo values from two to eight hours. For clenbuterol alone this difference was significant (P<0 01) at 10 hours, and for salbutamol alone significant differences were seen at 30 minutes (P<0-05) and one hour (P<0-01). The differences between the effects of clenbuterol and salbutamol were not quite significant, but were almost so at eight hours.
The results of the breathing scores are shown in Table 3 . Eighteen patients produced satisfactory records. While there is an apparent improvement with the active drugs this was not significant. The incidence and nature of side-effects is shown in Table 4 . The differences between the number of (Zimmer, 1976) . Clenbuterol is not subject to the action of catechol-o-methyl transferase and this partly explains its prolonged action, which may also be a function of its firm binding at the /8-receptor (Engelhardt, 1976 
